

Peter Hillmen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/295334/publications.pdf>

Version: 2024-02-01

383
papers

33,328
citations

9756

73
h-index

3997

176
g-index

390
all docs

390
docs citations

390
times ranked

17984
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies. <i>Leukemia</i> , 2022, 36, 271-274.	3.3	4
2	Management of cardiovascular complications of bruton tyrosine kinase inhibitors. <i>British Journal of Haematology</i> , 2022, 196, 70-78.	1.2	14
3	Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. <i>Haematologica</i> , 2022, 107, 1335-1346.	1.7	16
4	Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper. <i>British Journal of Haematology</i> , 2022, 196, 864-870.	1.2	10
5	Guideline for the treatment of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2022, 197, 544-557.	1.2	12
6	Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: <scp>Realâ€world</scp> findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry. <i>European Journal of Haematology</i> , 2022, 109, 197-204.	1.1	3
7	Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. <i>Blood Advances</i> , 2022, 6, 3440-3450.	2.5	91
8	No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib. <i>Leukemia and Lymphoma</i> , 2021, 62, 837-845.	0.6	1
9	A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia. <i>Trials</i> , 2021, 22, 38.	0.7	7
10	Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021, 12, 665.	5.8	9
11	Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. <i>New England Journal of Medicine</i> , 2021, 384, 1028-1037.	13.9	187
12	Realâ€world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK. <i>EJHaem</i> , 2021, 2, 219-227.	0.4	4
13	Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. <i>Leukemia</i> , 2021, 35, 3201-3211.	3.3	25
14	COSMIC, chemotherapy plus ofatumumab at standard or megaâ€dose in chronic lymphocytic leukaemia, a phase II randomised study. <i>British Journal of Haematology</i> , 2021, 194, 646-650.	1.2	1
15	First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 7500-7500.	0.8	34
16	Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 7523-7523.	0.8	20
17	The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UKâ€™s populationâ€based haematological malignancy research network 2004â€“2018. <i>European Journal of Haematology</i> , 2021, 107, 211-218.	1.1	19
18	Acalabrutinib in treatment-naive chronic lymphocytic leukemia. <i>Blood</i> , 2021, 137, 3327-3338.	0.6	47

#	ARTICLE	IF	CITATIONS
19	Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. <i>Leukemia</i> , 2021, 35, 3059-3072.	3.3	40
20	Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3441-3452.	0.8	266
21	<i><i>TP53</i></i> Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 5566-5575.	3.2	23
22	Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 3278-3282.	0.6	7
23	Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells. <i>Clinical Cancer Research</i> , 2021, 27, 5647-5659.	3.2	3
24	MDS-134: Efficacy and Safety at 48 Weeks of Pegcetacoplan in Adult Paroxysmal Nocturnal Hemoglobinuria Patients with Suboptimal Response to Prior Eculizumab Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S341-S342.	0.2	0
25	Poster: CLL-115: First Results of a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S220.	0.2	0
26	Poster: CLL-045: Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S221.	0.2	0
27	Poster: MDS-134: Efficacy and Safety at 48 Weeks of Pegcetacoplan in Adult Paroxysmal Nocturnal Hemoglobinuria Patients with Suboptimal Response to Prior Eculizumab Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S228.	0.2	0
28	Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion. <i>Haematologica</i> , 2021, 106, 2354-2363.	1.7	62
29	Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1&2 study. <i>Lancet Haematology</i> , 2021, 8, e912-e921.	2.2	32
30	Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial. <i>Blood</i> , 2021, 138, 642-642.	0.6	26
31	SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2021, 138, 396-396.	0.6	22
32	Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2021, 138, 3721-3721.	0.6	0
33	Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx). <i>Blood</i> , 2021, 138, 1548-1548.	0.6	5
34	Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial. <i>Blood</i> , 2021, 138, 2636-2636.	0.6	8
35	Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Early Results from Arm D of the SEQUOIA (BGB-3111-304) Trial. <i>Blood</i> , 2021, 138, 67-67.	0.6	19
36	3113 " FORTY-EIGHT WEEK EFFICACY AND SAFETY OF PEGCETACOPLAN IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND SUBOPTIMAL RESPONSE TO PRIOR ECULIZUMAB TREATMENT. <i>Experimental Hematology</i> , 2021, 100, S97.	0.2	3

#	ARTICLE	IF	CITATIONS
37	Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. <i>Leukemia</i> , 2020, 34, 787-798.	3.3	321
38	The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab. <i>Leukemia</i> , 2020, 34, 296-300.	3.3	23
39	Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 4042-4054.	0.8	141
40	Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2020, 97, 106432.	0.4	40
41	Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib. <i>Leukemia</i> , 2020, 34, 3404-3407.	3.3	7
42	COVID-19 infection in patients on anti-complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience. <i>British Journal of Haematology</i> , 2020, 191, e1-e4.	1.2	22
43	How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic. <i>HemaSphere</i> , 2020, 4, e432.	1.2	18
44	Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 2810-2818.	3.2	46
45	Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial. <i>Haematologica</i> , 2020, 105, e519.	1.7	8
46	Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. <i>Clinical Cancer Research</i> , 2020, 26, 2096-2103.	3.2	31
47	ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Future Oncology</i> , 2020, 16, 517-523.	1.1	52
48	Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial. <i>Haematologica</i> , 2020, 105, 2868-2871.	1.7	2
49	Presentation clinical, haematological and immunophenotypic features of 1081 patients with GPIIb/IIIa-deficient (paroxysmal nocturnal haemoglobinuria) cells detected by flow cytometry. <i>British Journal of Haematology</i> , 2020, 189, 954-966.	1.2	16
50	Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1. <i>Haematologica</i> , 2020, 105, 2440-2447.	1.7	31
51	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. <i>Blood</i> , 2020, 135, 1204-1213.	0.6	130
52	A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial. <i>British Journal of Haematology</i> , 2020, 190, 736-740.	1.2	9
53	DAPK3 participates in the mRNA processing of immediate early genes in chronic lymphocytic leukaemia. <i>Molecular Oncology</i> , 2020, 14, 1268-1281.	2.1	3
54	Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab. <i>American Journal of Hematology</i> , 2020, 95, 944-952.	2.0	3

#	ARTICLE	IF	CITATIONS
55	Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL. <i>Blood</i> , 2020, 135, 411-428.	0.6	17
56	Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. <i>Haematologica</i> , 2020, 106, 230-237.	1.7	77
57	SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP. <i>Cell Reports</i> , 2020, 31, 107640.	2.9	16
58	Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies. <i>British Journal of Haematology</i> , 2020, 191, 476-485.	1.2	38
59	Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) Trial. <i>Blood</i> , 2020, 136, 24-25.	0.6	3
60	Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial. <i>Blood</i> , 2020, 136, 11-12.	0.6	19
61	Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 52-54.	0.6	4
62	Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx). <i>Blood</i> , 2020, 136, 19-21.	0.6	37
63	Management of Meningococcal Disease Risk in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) on Complement Inhibitors: 18 Years' Experience from the UK National PNH Service in Leeds. <i>Blood</i> , 2020, 136, 5-6.	0.6	3
64	Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: Mature results from phase II study demonstrating durable remissions and long-term tolerability.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8024-8024.	0.8	11
65	Safety of acalabrutinib (Acala) monotherapy in hematologic malignancies: Pooled analysis from clinical trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8064-8064.	0.8	8
66	A Phase 1b-2 Study of KRT-232, a First-in-Class, Oral, Small Molecule Inhibitor of Murine Double Minute 2 (MDM2), in Combination with Acalabrutinib for the Treatment of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or R/R Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2020, 136, 23-24.	0.6	2
67	Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2722-2729.	0.8	197
68	Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 715-722.e6.	0.2	35
69	Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. <i>Lancet Haematology</i> , 2019, 6, e366-e374.	2.2	49
70	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 1353-1363.	2.0	305
71	An Improved Benefit-Risk Profile of Duvelisib in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Received ≥2 Prior Therapies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S276.	0.2	0
72	Five-Year Follow-Up After Ibrutinib Therapy for First-Line Treatment of Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S274.	0.2	0

#	ARTICLE	IF	CITATIONS
73	Trial re-investment to build better research for better impact. <i>Lancet, The</i> , 2019, 394, 635-636.	6.3	2
74	Telomere length predicts for outcome to FCR chemotherapy in CLL. <i>Leukemia</i> , 2019, 33, 1953-1963.	3.3	12
75	The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease. <i>BMC Cancer</i> , 2019, 19, 471.	1.1	19
76	Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells. <i>Oncogenesis</i> , 2019, 8, 32.	2.1	10
77	Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 1391-1402.	0.8	177
78	Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag. <i>Haematologica</i> , 2019, 104, e494-e496.	1.7	17
79	Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. <i>Blood</i> , 2019, 133, 2031-2042.	0.6	178
80	Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , 2019, 133, 2765-2775.	0.6	63
81	Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 269-277.	0.8	250
82	Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. <i>British Journal of Haematology</i> , 2019, 185, 297-310.	1.2	148
83	Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. <i>American Journal of Hematology</i> , 2019, 94, 554-562.	2.0	27
84	Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials. <i>Blood Advances</i> , 2019, 3, 2474-2481.	2.5	25
85	Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. <i>Blood Advances</i> , 2019, 3, 1553-1562.	2.5	145
86	Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. <i>Blood Advances</i> , 2019, 3, 1799-1807.	2.5	90
87	Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria. <i>Haematologica</i> , 2019, 104, e94-e96.	1.7	14
88	Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. <i>Leukemia and Lymphoma</i> , 2019, 60, 1000-1005.	0.6	17
89	Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia. <i>Blood</i> , 2019, 134, 1740-1740.	0.6	1
90	Real-World Treatment Patterns and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib in the UK: A Preliminary Analysis. <i>Blood</i> , 2019, 134, 5885-5885.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial. <i>Blood</i> , 2019, 134, 356-356.	0.6	1
92	Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 355-355.	0.6	16
93	Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial. <i>Blood</i> , 2019, 134, 499-499.	0.6	23
94	Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study. <i>Blood</i> , 2019, 134, 3039-3039.	0.6	1
95	Subcutaneous Alemtuzumab Has Activity in Treatment-Naïve Patients with Acquired Aplastic Anemia. <i>Blood</i> , 2019, 134, 2503-2503.	0.6	1
96	Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7510-7510.	0.8	1
97	Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL): Final analysis of the phase 3 COMPLEMENT 1 trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7528-7528.	0.8	2
98	ALPINE: Phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS7572-TPS7572.	0.8	8
99	Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2019, 134, 3054-3054.	0.6	2
100	Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2019, 134, 4307-4307.	0.6	1
101	Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia. <i>JAMA Oncology</i> , 2018, 4, 712.	3.4	20
102	Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. <i>British Journal of Haematology</i> , 2018, 180, 666-679.	1.2	51
103	iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. <i>Blood</i> , 2018, 131, 2745-2760.	0.6	1,069
104	Venetoclax+Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2018, 378, 1107-1120.	13.9	684
105	Concurrent treatment of aplastic anemia/paroxysmal nocturnal hemoglobinuria syndrome with immunosuppressive therapy and eculizumab: a UK experience. <i>Haematologica</i> , 2018, 103, e345-e347.	1.7	18
106	A multicentre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, prolymphocytic leukaemia or mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018, 182, 429-433.	1.2	23
107	Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 121-128.	0.7	133
108	Highly selective SYK inhibitor, GSK143, abrogates survival signals in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2018, 182, 927-930.	1.2	1

#	ARTICLE	IF	CITATIONS
109	Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1973-1980.	0.8	257
110	The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. <i>Blood</i> , 2018, 132, 2446-2455.	0.6	261
111	Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program. <i>Haematologica</i> , 2018, 103, e204-e206.	1.7	8
112	Clinical-grade validation of whole genome sequencing reveals robust detection of low-frequency variants and copy number alterations in CLL. <i>British Journal of Haematology</i> , 2018, 182, 412-417.	1.2	19
113	The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study. <i>Clinical Cancer Research</i> , 2018, 24, 5048-5057.	3.2	38
114	Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 648-657.e15.	0.2	62
115	Guideline for the treatment of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2018, 182, 344-359.	1.2	29
116	Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. <i>American Journal of Hematology</i> , 2018, 93, 1402-1410.	2.0	24
117	Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 803-813.e7.	0.2	32
118	Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. <i>British Journal of Haematology</i> , 2018, 182, 504-512.	1.2	37
119	Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2018, 24, 4371-4379.	3.2	127
120	Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. <i>Haematologica</i> , 2018, 103, 1502-1510.	1.7	111
121	Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib Exposure. <i>Blood</i> , 2018, 132, 181-181.	0.6	5
122	Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study. <i>Blood</i> , 2018, 132, 182-182.	0.6	20
123	MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 184-184.	0.6	8
124	Minimal Residual Disease Status with Venetoclax Monotherapy Is Associated with Progression-Free Survival in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 3134-3134.	0.6	5
125	Acalabrutinib in Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study. <i>Blood</i> , 2018, 132, 692-692.	0.6	17
126	Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria: Pharmacokinetics and Pharmacodynamics Observed in Two Phase 3 Randomized, Multicenter Studies. <i>Blood</i> , 2018, 132, 626-626.	0.6	7

#	ARTICLE	IF	CITATIONS
127	A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2018, 132, 2330-2330.	0.6	4
128	Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 3135-3135.	0.6	1
129	Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study. <i>Blood</i> , 2018, 132, 1856-1856.	0.6	2
130	First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study. <i>Blood</i> , 2018, 132, 185-185.	0.6	2
131	The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study. <i>Blood</i> , 2018, 132, 3140-3140.	0.6	2
132	Duvelisib inhibition of chemokines in patients with CLL (DUO study) and iNHL (DYNAMO study).. <i>Journal of Clinical Oncology</i> , 2018, 36, 12048-12048.	0.8	2
133	High, durable minimal residual disease negativity (MRD ⁺) with venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7508-7508.	0.8	2
134	The efficacy of duvelisib monotherapy following disease progression on ofatumumab monotherapy in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7533-7533.	0.8	1
135	Phase 3 zanubrutinib (BGB-3111) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS7581-TPS7581.	0.8	5
136	Highly Comprehensive Genomic Testing for CLL: WGS, One Key to CLL Patient Stratification. <i>Blood</i> , 2018, 132, 3115-3115.	0.6	0
137	Telomere Length Predicts for Outcome to FCR Chemoimmunotherapy in CLL. <i>Blood</i> , 2018, 132, 1854-1854.	0.6	0
138	Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy. <i>Blood</i> , 2018, 132, 4394-4394.	0.6	0
139	Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2017, 18, 297-311.	5.1	219
140	Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. <i>British Journal of Haematology</i> , 2017, 178, 286-291.	1.2	55
141	USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status. <i>Blood</i> , 2017, 130, 156-166.	0.6	60
142	Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. <i>Blood</i> , 2017, 129, 2612-2615.	0.6	111
143	Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation. <i>British Journal of Haematology</i> , 2017, 176, 573-582.	1.2	13
144	Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. <i>Haematologica</i> , 2017, 102, 1796-1805.	1.7	200

#	ARTICLE	IF	CITATIONS
145	Polymyalgia rheumatica development in a patient under PI3K inhibitor therapy for chronic lymphocytic leukaemia. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-221065.	0.2	2
146	GA101 (obinutuzumab) monoclonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial. <i>Trials</i> , 2017, 18, 353.	0.7	5
147	Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. <i>Trials</i> , 2017, 18, 387.	0.7	31
148	Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial. <i>Health Technology Assessment</i> , 2017, 21, 1-374.	1.3	14
149	COSMOS: MOR208 plus idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (BTKi) – A two-cohort phase II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS7567-TPS7567.	0.8	0
150	Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. <i>Blood</i> , 2017, 130, LBA-2-LBA-2.	0.6	14
151	Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria. <i>American Journal of Hematology</i> , 2016, 91, E16-7.	2.0	13
152	Minimal residual disease is an independent predictor for 10-year survival in CLL. <i>Blood</i> , 2016, 128, 2770-2773.	0.6	106
153	Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*. <i>Leukemia and Lymphoma</i> , 2016, 57, 1291-1299.	0.6	17
154	Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL. <i>Acta Oncologica</i> , 2016, 55, 1115-1120.	0.8	20
155	Guidelines for the diagnosis and management of adult aplastic anaemia. <i>British Journal of Haematology</i> , 2016, 172, 187-207.	1.2	539
156	Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. <i>Lancet Oncology</i> , The, 2016, 17, 1409-1418.	5.1	290
157	<sc>NCRI</sc> phase <sc>II</sc> study of <sc>CHOP</sc> in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome. <i>British Journal of Haematology</i> , 2016, 175, 43-54.	1.2	53
158	Outcomes with Ibrutinib by Line of Therapy in Patients with CLL: Analyses from Phase 3 Data. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S43.	0.2	0
159	Phase 3 Study of Ibrutinib versus Chlorambucil in Patients ≥65 Years with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S45-S46.	0.2	0
160	ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. <i>Blood</i> , 2016, 127, 582-595.	0.6	214
161	The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. <i>Haematologica</i> , 2016, 101, 235-240.	1.7	24
162	Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial. <i>Trials</i> , 2016, 17, 456.	0.7	1

#	ARTICLE	IF	CITATIONS
163	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 323-332.	13.9	785
164	Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2). <i>Blood</i> , 2016, 128, 2041-2041.	0.6	4
165	11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies. <i>Blood</i> , 2016, 128, 2042-2042.	0.6	9
166	Molecular Mechanisms of Ibrutinib Resistance: Defining a Logical Approach to Improving Targeted Therapy in CLL. <i>Blood</i> , 2016, 128, 2046-2046.	0.6	3
167	Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Icicle Extension Study. <i>Blood</i> , 2016, 128, 2049-2049.	0.6	1
168	Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 234-234.	0.6	36
169	Compartment Effect on the Prognostic Significance of MRD Detection in CLL: Impact of Treatment Type and Duration of Follow-up. <i>Blood</i> , 2016, 128, 3226-3226.	0.6	9
170	Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2016, 128, 4383-4383.	0.6	7
171	Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4395-4395.	0.6	7
172	Acalabrutinib Monotherapy in Patients with Richter Transformation from the Phase 1/2 ACE-CL-001 Clinical Study. <i>Blood</i> , 2016, 128, 60-60.	0.6	40
173	Acalabrutinib Monotherapy in Patients with Ibrutinib Intolerance: Results from the Phase 1/2 ACE-CL-001 Clinical Study. <i>Blood</i> , 2016, 128, 638-638.	0.6	23
174	Outcomes with ibrutinib by line of therapy in patients with CLL: Analyses from phase III data.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7520-7520.	0.8	10
175	Acalabrutinib, a second-generation bruton tyrosine kinase (Btk) inhibitor, in previously untreated chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7521-7521.	0.8	12
176	Patterns of hepatitis B reactivation and liver test abnormalities in patients with chronic lymphocytic leukemia (CLL) treated with idelalisib plus an anti-CD20 antibody.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7533-7533.	0.8	1
177	A phase II study of MOR208 plus idelalisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (MIRACLE).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS7572-TPS7572.	0.8	0
178	Differing Mutational Profiles of IgHV+ and IgHV- Patients Revealed By Whole Genome Sequencing in Chronic Lymphocytic Leukaemia (CLL). <i>Blood</i> , 2016, 128, 5590-5590.	0.6	0
179	Concurrent Treatment of Aplastic Anaemia (AA) with Immunosuppressive Therapy and Paroxysmal Nocturnal Hemoglobinuria (PNH) with Eculizumab: A UK Experience. <i>Blood</i> , 2016, 128, 2683-2683.	0.6	11
180	Identifying High-Risk CLL to Predict Early Relapse after FCR Based Treatment Using Whole Genome Sequencing: First Results from the Genomics England CLL Pilot. <i>Blood</i> , 2016, 128, 2022-2022.	0.6	5

#	ARTICLE	IF	CITATIONS
181	Evaluation of Immune Mechanisms to Understand Idelalislib-Associated Diarrhea-Colitis. <i>Blood</i> , 2016, 128, 5588-5588.	0.6	0
182	Natural killer (NK) cell function in paroxysmal nocturnal hemoglobinuria: a deficiency of NK cells, but not an NK cell deficiency. <i>Blood</i> , 2015, 125, 1351-1352.	0.6	8
183	Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib. <i>Blood</i> , 2015, 125, 1673-1673.	0.6	17
184	Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. <i>Blood</i> , 2015, 126, 2110-2117.	0.6	94
185	Ofatumumab retreatment and maintenance in fludarabine- refractory chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2015, 170, 40-49.	1.2	14
186	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 2425-2437.	13.9	1,261
187	Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Who Have Undergone Prior Allogeneic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S82-S83.	2.0	2
188	Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. <i>Haematologica</i> , 2015, 100, 511-516.	1.7	42
189	Paroxysmal Nocturnal Hemoglobinuria in Pregnancy. , 2015, , 327-342.		1
190	Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. <i>Lancet</i> , The, 2015, 385, 1873-1883.	6.3	296
191	Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. <i>Haematologica</i> , 2015, 100, e311-4.	1.7	15
192	The Level of Residual CLL Objectively Predicts the Outcome of Patients Following FCR-Based Therapy with Sequential Benefits per Log Depletion and Improved Post-Treatment Monitoring. <i>Blood</i> , 2015, 126, 1717-1717.	0.6	3
193	Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials. <i>Blood</i> , 2015, 126, 2944-2944.	0.6	23
194	Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project. <i>Blood</i> , 2015, 126, 4146-4146.	0.6	2
195	Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331). <i>Blood</i> , 2015, 126, 494-494.	0.6	23
196	Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM). <i>Blood</i> , 2015, 126, 495-495.	0.6	2
197	Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study. <i>Blood</i> , 2015, 126, 833-833.	0.6	15
198	Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study. <i>Blood</i> , 2015, 126, LBA-5-LBA-5.	0.6	16

#	ARTICLE	IF	CITATIONS
199	The Bruton Tyrosine Kinase (Btk) Inhibitor ACP-196: Marked Activity in Relapsed/Refractory CLL with a Favorable Safety Profile. <i>Blood</i> , 2015, 126, 831-831.	0.6	0
200	Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 365-365.	0.6	0
201	Patterns of Lymphocytosis in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Treated with Idelalisib. <i>Blood</i> , 2015, 126, 2952-2952.	0.6	0
202	Analysis of Prognostic Factors Predictive of Complete Response (CR) to Ibrutinib in Patients with CLL/SLL. <i>Blood</i> , 2015, 126, 4153-4153.	0.6	1
203	Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. <i>Haematologica</i> , 2014, 99, 922-929.	1.7	195
204	A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2014, 167, 466-477.	1.2	30
205	Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2014, 370, 997-1007.	13.9	1,535
206	Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 213-223.	13.9	1,427
207	Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1236-1241.	0.8	109
208	Independent prognostic significance of minimal residual disease status in chronic lymphocytic leukaemia. <i>Lancet, The</i> , 2014, 383, S66.	6.3	4
209	SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. <i>Blood</i> , 2014, 123, 1021-1031.	0.6	205
210	Mutational Landscape of 118 Relapsed Chronic Lymphocytic Leukemia Clinical Trial Samples; Evidence for a Multiple-Hit Profile Using Targeted Next Generation Sequencing. <i>Blood</i> , 2014, 124, 1974-1974.	0.6	1
211	Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy. <i>Blood</i> , 2014, 124, 1990-1990.	0.6	10
212	Gene Mutations and Treatment Outcome in CLL Patients Treated with Chlorambucil (Chl) or Ofatumumab-Chl (O-Chl): Results from the Phase III Study COMPLEMENT1 (OMB110911). <i>Blood</i> , 2014, 124, 1992-1992.	0.6	4
213	Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE-17 Trial. <i>Blood</i> , 2014, 124, 327-327.	0.6	33
214	Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIGÂ®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors. <i>Blood</i> , 2014, 124, 330-330.	0.6	61
215	Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2014, 124, 3331-3331.	0.6	24
216	Clinical and Immunological Characterisation of Coversin, a Novel Small Protein Inhibitor of Complement C5 with Potential As a Therapeutic Agent in PNH and Other Complement Mediated Disorders. <i>Blood</i> , 2014, 124, 4280-4280.	0.6	17

#	ARTICLE	IF	CITATIONS
217	Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATE™ Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2014, 124, 4696-4696.	0.6	12
218	Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Have Undergone Prior Allogeneic Stem Cell Transplant. <i>Blood</i> , 2014, 124, 4697-4697.	0.6	11
219	Autoimmune Hemolytic Anemia and Immune Mediated Thrombocytopenia in the Phase III RESONATE™ Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Including a Case Report. <i>Blood</i> , 2014, 124, 5654-5654.	0.6	13
220	DUO: A phase 3 trial of the PI3K-Î³ inhibitor IPI-145 versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS7122-TPS7122.	0.8	1
221	A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study. <i>Blood</i> , 2014, 124, 1976-1976.	0.6	2
222	The Identification of Further Minimal Regions of Overlap in Chronic Lymphocytic Leukemia Using High-Resolution SNP Arrays. <i>Blood</i> , 2014, 124, 3315-3315.	0.6	0
223	Towards Response Prediction Using Integrated Genomics in Chronic Lymphocytic Leukaemia: Results on 250 First-Line FCR Treated Patients from UK Clinical Trials. <i>Blood</i> , 2014, 124, 1942-1942.	0.6	0
224	Improving cytopenia with splenic artery embolization in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab. <i>International Journal of Hematology</i> , 2013, 98, 716-718.	0.7	11
225	Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 2013, 162, 62-73.	1.2	320
226	Thrombosis in paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2013, 121, 4985-4996.	0.6	359
227	TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study). <i>Blood</i> , 2013, 122, 1638-1638.	0.6	3
228	Results Of The Randomised Phase II NCRI Arctic (Attenuated dose Rituximab with ChemoTherapy In CLL) Trial Of Low Dose Rituximab In Previously Untreated CLL. <i>Blood</i> , 2013, 122, 1639-1639.	0.6	3
229	A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study. <i>Blood</i> , 2013, 122, 1645-1645.	0.6	2
230	Red Cell Complement Loading In PNH Patients On Eculizumab Is Associated With a C3 Polymorphism Which Influences C3 Function, Predicts For Increased Extravascular Hemolysis and Provides a Rationale For C3 Inhibition. <i>Blood</i> , 2013, 122, 2466-2466.	0.6	10
231	Insights Into The Natural History Of Paroxysmal Nocturnal Hemoglobinuria (PNH): Analysis Of The Presenting Clinical, Haematological and Flow Cytometric Features Of 705 Patients Leads To Improved Classification and Prediction Of Clinical Course. <i>Blood</i> , 2013, 122, 3718-3718.	0.6	1
232	NOTCH1 Mutation and Treatment Outcome In CLL Patients Treated With Chlorambucil (Chl) Or Ofatumumab-Chl (O-Chl): Results From The Phase III Study Complement 1 (OMB110911). <i>Blood</i> , 2013, 122, 527-527.	0.6	9
233	Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911). <i>Blood</i> , 2013, 122, 528-528.	0.6	49
234	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013, 122, LBA-6-LBA-6.	0.6	4

#	ARTICLE	IF	CITATIONS
235	Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 417-423.	0.6	56
236	Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2012, 159, 541-564.	1.2	127
237	Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 1647-1655.	0.8	152
238	Lessons from an incidental diagnosis of paroxysmal nocturnal haemoglobinuria. <i>Annals of Hematology</i> , 2012, 91, 975-976.	0.8	0
239	Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function. <i>British Journal of Haematology</i> , 2012, 158, 409-414.	1.2	48
240	Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Report of All 153 Patients Treated in the UK. <i>Blood</i> , 2012, 120, 3472-3472.	0.6	13
241	Improved Outcomes of Budd-Chiari Syndrome in Paroxysmal Nocturnal Hemoglobinuria with Eculizumab Therapy. <i>Blood</i> , 2012, 120, 3478-3478.	0.6	16
242	Updated Interim Results of the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Patients with Relapsed or Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009) Tj ETQq0 0 OrgBT /Overdock 10 T		
243	Aberrant Expression of Neuronal Receptors in CLL: Potential Targets with Therapeutic Implications. <i>Blood</i> , 2012, 120, 3899-3899.	0.6	0
244	Eculizumab Protects Against TE and Prolongs Survival in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Study. <i>Blood</i> , 2012, 120, 3480-3480.	0.6	0
245	SAMHD1, A Putative Tumour Suppressor, Is Recurrently Mutated in Chronic Lymphocytic Leukaemia, and Is Associated with Poor Risk Features. <i>Blood</i> , 2012, 120, 713-713.	0.6	0
246	Update in paroxysmal nocturnal hemoglobinuria. <i>Clinical Advances in Hematology and Oncology</i> , 2012, 10, 391-3.	0.3	1
247	Richter's syndrome: CLL taking a turn for the worse. <i>Oncology</i> , 2012, 26, 1155-6.	0.4	1
248	Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. <i>Blood</i> , 2011, 117, 6786-6792.	0.6	410
249	2.48 Identification and Validation of Potential Targets for the Diagnosis and Therapy of CLL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S189-S190.	0.2	0
250	3.14 The Influence of Genetic Background and Infectious Exposure on the Development of Chronic Lymphocytic Leukaemia and Other B-Cell Malignancies: Evidence from High-Sensitivity Screening in Leeds and Rural Uganda. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S205-S206.	0.2	0
251	5.46 NCRN CLL207 Study of Alemtuzumab Consolidation in Chronic Lymphocytic Leukaemia: Response Assessment Follow-up and Pharmacokinetic studies (on Behalf of the NCRI CLL Trials Sub-Group). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S275-S276.	0.2	0
252	A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2011, 152, 570-578.	1.2	38

#	ARTICLE	IF	CITATIONS
253	Ofatumumab in advanced stage chronic lymphocytic leukaemia: results of the UK named patient compassionate use programme. <i>British Journal of Haematology</i> , 2011, 155, 519-521.	1.2	6
254	A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial. <i>Cancer</i> , 2011, 117, 2452-2460.	2.0	10
255	Using the Biology of Chronic Lymphocytic Leukemia to Choose Treatment. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 104-109.	0.9	28
256	Clinical Characteristics of Classic Paroxysmal Nocturnal Hemoglobinuria (PNH) in Pediatric Patients: A Comparison with Classic PNH in Adults. An International PNH Registry Study. <i>Blood</i> , 2011, 118, 2102-2102.	0.6	2
257	Continued Benefit From Prolonged Treatment with Eculizumab in 130 Patients with PNH in the UK: Home Delivery of Eculizumab Is Safe, Convenient and Associated with Very High Levels of Patient Satisfaction. <i>Blood</i> , 2011, 118, 4368-4368.	0.6	1
258	The Addition of Rituximab to Fludarabine and Cyclophosphamide (FC) Improves Overall Survival in Newly Diagnosed Mantle Cell Lymphoma (MCL): Results of the Randomised UK National Cancer Research Institute (NCRI) Trial. <i>Blood</i> , 2011, 118, 440-440.	0.6	9
259	An In Vitro model of the Bone Marrow in Paroxysmal Nocturnal Hemoglobinuria Showing a Direct Effect of T-Cells within the Bone Marrow Allowing Clonal Expansion. <i>Blood</i> , 2011, 118, 731-731.	0.6	0
260	Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. <i>Haematologica</i> , 2010, 95, 567-573.	1.7	166
261	Eradicating Minimal Residual Disease in Chronic Lymphocytic Leukemia: Should This Be the Goal of Treatment?. <i>Current Hematologic Malignancy Reports</i> , 2010, 5, 35-44.	1.2	18
262	Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. <i>American Journal of Hematology</i> , 2010, 85, 553-559.	2.0	174
263	Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 2010, 149, 414-425.	1.2	137
264	The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. <i>British Journal of Haematology</i> , 2010, 149, 446-450.	1.2	122
265	Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1749-1755.	0.8	541
266	Paroxysmal Nocturnal Hemoglobinuria – Hemolysis before and after Eculizumab. <i>New England Journal of Medicine</i> , 2010, 363, 2270-2272.	13.9	59
267	Clinical and diagnostic implications of monoclonal B-cell lymphocytosis. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 61-69.	0.7	20
268	Chronic lymphocytic leukaemia – moving towards cure?. <i>Lancet, The</i> , 2010, 376, 1122-1124.	6.3	7
269	Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study). <i>Blood</i> , 2010, 116, 1376-1376.	0.6	1
270	Evaluation of Paroxysmal Nocturnal Hemoglobinuria Disease Burden: The Patient's Perspective. A Report From the International PNH Registry.. <i>Blood</i> , 2010, 116, 1525-1525.	0.6	5

#	ARTICLE	IF	CITATIONS
271	Use of Blood Transfusions In Paroxysmal Nocturnal Hemoglobinuria Patients with and without Aplastic Anemia Enrolled In the Global PNH Registry. <i>Blood</i> , 2010, 116, 2241-2241.	0.6	6
272	Long Term Safety and Efficacy of Sustained Eculizumab Treatment In Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). <i>Blood</i> , 2010, 116, 4237-4237.	0.6	4
273	NCRN CLL207 Study of Alemtuzumab Consolidation In CLL: Final Response Assessment and Early Follow-up (on Behalf of the NCRI CLL Trials Sub-Group). <i>Blood</i> , 2010, 116, 60-60.	0.6	1
274	Long Term Treatment with Eculizumab In Paroxysmal Nocturnal Hemoglobinuria (PNH): Sustained Efficacy and Improved Survival. <i>Blood</i> , 2010, 116, 639-639.	0.6	2
275	A Multi-Center, Open-Label, Phase I Study of Single Agent RG7112, A First In Class p53-MDM2 Antagonist, In Patients with Relapsed/Refractory Acute Myeloid and Lymphoid Leukemias (AML/ALL) and Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphomas (CLL/SCLL). <i>Blood</i> , 2010, 116, 657-657.	0.6	16
276	Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study. <i>Blood</i> , 2010, 116, 697-697.	0.6	20
277	Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 921-921.	0.6	9
278	Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group). <i>Blood</i> , 2010, 116, 922-922.	0.6	3
279	CD5-Negative Monoclonal B-Cell Lymphocytosis (MBL) Is Detectable In 9% of Adults Aged Over 40 but Phenotypes Associated with Clinically Common Non-Hodgkin Lymphomas Are Infrequent (<2%). <i>Blood</i> , 2010, 116, 2002-2002.	0.6	0
280	The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 911.	0.9	33
281	Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. <i>Human Mutation</i> , 2009, 30, 1567-1573.	1.1	107
282	Development and evaluation of a stabilized wholeâ€blood preparation as a process control material for screening of paroxysmal nocturnal hemoglobinuria by flow cytometry. <i>Cytometry Part B - Clinical Cytometry</i> , 2009, 76B, 47-55.	0.7	35
283	Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advancedâ€stage, relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2009, 144, 78-85.	1.2	28
284	Response: Letters regarding <i>Blood</i> . 2008;111:5446-5456 by Hanson et al and Mulligan et al. <i>Blood</i> , 2009, 113, 6497-6498.	0.6	5
285	A Spontaneous Reduction of Clone Size in Paroxysmal Nocturnal Hemoglobinuria Patients Treated with Eculizumab for Greater Than 12 Months.. <i>Blood</i> , 2009, 114, 1992-1992.	0.6	4
286	Effects of Eculizumab Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Concurrent Immunosuppressive Therapy for Bone Marrow Insufficiency.. <i>Blood</i> , 2009, 114, 3012-3012.	0.6	3
287	An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL).. <i>Blood</i> , 2009, 114, 3428-3428.	0.6	6
288	Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab.. <i>Blood</i> , 2009, 114, 3433-3433.	0.6	7

#	ARTICLE	IF	CITATIONS
289	Minimal Residual Disease Is a Predictor for Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia (CLL) That Is Independent of the Type or Line of Therapy.. Blood, 2009, 114, 540-540.	0.6	12
290	Five-Year Follow-up of Monoclonal B-Cell Lymphocytosis (MBL) in Individuals with a Normal Blood Count: Expansion of the Abnormal B-Cell Compartment but No Progressive Disease.. Blood, 2009, 114, 59-59.	0.6	8
291	A Global Registry of Patients with Paroxysmal Nocturnal Hemoglobinuria.. Blood, 2009, 114, 3007-3007.	0.6	0
292	Assessing minimal residual disease in chronic lymphocytic leukemia. Current Hematologic Malignancy Reports, 2008, 3, 47-53.	1.2	9
293	A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nature Genetics, 2008, 40, 1204-1210.	9.4	329
294	Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology, 2008, 142, 263-272.	1.2	50
295	Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2008, 359, 575-583.	13.9	518
296	Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute's Working Group 1996 guidelines. Blood, 2008, 111, 5446-5456.	0.6	2,887
297	Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood, 2008, 111, 1840-1847.	0.6	534
298	Development of EBV-associated diffuse large B-cell lymphoma in Waldenström macroglobulinemia and mantle cell lymphoma. Leukemia and Lymphoma, 2008, 49, 1618-1619.	0.6	11
299	The Role of Complement Inhibition in PNH. Hematology American Society of Hematology Education Program, 2008, 2008, 116-123.	0.9	25
300	Which Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Should Be Treated with Eculizumab?. Hematology American Society of Hematology Education Program, 2008, 2008, 35-35.	0.9	6
301	Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial. Blood, 2008, 112, 328-328.	0.6	31
302	Modification of the Eculizumab Dose to Successfully Manage Intravascular Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria.. Blood, 2008, 112, 3441-3441.	0.6	19
303	Successful Pregnancy Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Long-Term Eculizumab Treatment. Blood, 2008, 112, 4576-4576.	0.6	3
304	Home Infusion of Eculizumab: A Unique and Innovative Model of Drug Delivery to Reduce Treatment-Associated Burden and Enhance Quality of Life for Patients with PNH. Blood, 2008, 112, 4671-4671.	0.6	1
305	Eculizumab Reduces Pulmonary Hypertension through Inhibition of Hemolysis-Associated Nitric Oxide Consumption in Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2008, 112, 486-486.	0.6	4
306	Defective Telomerase in Familial Myelodysplasia and Leukemia. Blood, 2008, 112, 849-849.	0.6	0

#	ARTICLE	IF	CITATIONS
307	TP53 Deletion in CLL: The Significance of Borderline Level Deletion. Blood, 2008, 112, 4178-4178.	0.6	6
308	Differential Protein Expression in MBL and CLL: LAIR1 Is a Powerful Surface Marker for Identifying Cases with Adverse Cellular Features.. Blood, 2008, 112, 2076-2076.	0.6	0
309	Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2007, 25, 5616-5623.	0.8	533
310	Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood, 2007, 110, 4123-4128.	0.6	481
311	Minimal residual disease assessment in chronic lymphocytic leukaemia. Best Practice and Research in Clinical Haematology, 2007, 20, 499-512.	0.7	15
312	Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria. Cytometry Part B - Clinical Cytometry, 2007, 72B, 291-298.	0.7	39
313	Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?. British Journal of Haematology, 2007, 136, 379-392.	1.2	25
314	Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. British Journal of Haematology, 2007, 137, 181-192.	1.2	130
315	Bâ€cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle. British Journal of Haematology, 2007, 139, 600-604.	1.2	35
316	The biological and clinical relationship between CD5+23+monoclonal B-cell lymphocytosis and chronic lymphocytic leukaemia. British Journal of Haematology, 2007, 139, 724-729.	1.2	32
317	Outreach monitoring service for patients with indolent B-cell and plasma cell disorders: a UK experience. British Journal of Haematology, 2007, 139, 845-848.	1.2	11
318	Eradication of Minimal Residual Disease with Alemtuzumab in Chronic Lymphocytic Leukemia Is Associated with Prolonged Survival and Is an Appropriate Therapeutic Endpoint for Relapsed CLL.. Blood, 2007, 110, 3114-3114.	0.6	5
319	Sustained Improvements in Transfusion Requirements, Fatigue and Thrombosis with Eculizumab Treatment in Paroxysmal Nocturnal Hemoglobinuria.. Blood, 2007, 110, 3672-3672.	0.6	3
320	High Incidence of Progression to Chronic Renal Insufficiency in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).. Blood, 2007, 110, 3678-3678.	0.6	6
321	NCRI CLL201 Trial: A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) with or without Rituximab in Previously Treated CLL.. Blood, 2007, 110, 752-752.	0.6	11
322	Monoclonal B-Cell Lymphocytosis (MBL) Is a Precursor State for Chronic Lymphocytic Leukemia (CLL) with 1% Progression Per Year.. Blood, 2007, 110, 749-749.	0.6	1
323	The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. New England Journal of Medicine, 2006, 355, 1233-1243.	13.9	1,060
324	Protection of erythrocytes from human complementâ€™mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy. Blood, 2006, 107, 2131-2137.	0.6	49

#	ARTICLE	IF	CITATIONS
325	Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency. <i>Nature Medicine</i> , 2006, 12, 846-851.	15.2	196
326	Beyond Detectable Minimal Residual Disease in Chronic Lymphocytic Leukemia. <i>Seminars in Oncology</i> , 2006, 33, 23-28.	0.8	9
327	The Terminal Complement Inhibitor Eculizumab Reduces Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria.. <i>Blood</i> , 2006, 108, 123-123.	0.6	25
328	Treatment with the Terminal Complement Inhibitor Eculizumab Improves Anemia in Patients with Paroxysmal Nocturnal Hemoglobinuria: Phase III Triumph Study Results.. <i>Blood</i> , 2006, 108, 124-124.	0.6	13
329	Incidence of Genomic Aberrations and Associated Efficacy from a Phase III Study Comparing Alemtuzumab (CAMPATH®; MABCAMPATH®) vs Chlorambucil as First Line Therapy for B-Cell Chronic Lymphocytic Leukemia (BCLL).. <i>Blood</i> , 2006, 108, 2092-2092.	0.6	4
330	Monoclonal B-Cell Lymphocytosis (MBL) and CLL Show Intraclonal Variation: Cases Classified as "Unmutated" Have the Greatest Clonal Diversity.. <i>Blood</i> , 2006, 108, 30-30.	0.6	6
331	Alemtuzumab (CAMPATH®, MABCAMPATH®) Has Superior Progression Free Survival (PFS) vs Chlorambucil as Front-Line Therapy for Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (BCLL).. <i>Blood</i> , 2006, 108, 301-301.	0.6	7
332	The Lack of Survival Differences in Randomised Trials in CLL May Be Related to the Effect of Second Line Therapies. A Report from the LRF CLL4 Trial.. <i>Blood</i> , 2006, 108, 304-304.	0.6	3
333	Final Report of the UKCLLO2 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group).. <i>Blood</i> , 2006, 108, 34-34.	0.6	9
334	Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Interim Shepherd Phase III Clinical Study.. <i>Blood</i> , 2006, 108, 971-971.	0.6	5
335	Blockade of Intravascular Hemolysis in PNH with the Terminal Complement Inhibitor Eculizumab Unmasks Low-Level Hemolysis Potentially Occurring through C3 Opsonization.. <i>Blood</i> , 2006, 108, 972-972.	0.6	5
336	High Definition Contrast-Enhanced MR Imaging in Paroxysmal Nocturnal Hemoglobinuria (PNH) Suggests a High Frequency of Subclinical Thrombosis.. <i>Blood</i> , 2006, 108, 979-979.	0.6	6
337	The Incidence and Prevalence of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Survival of Patients in Yorkshire.. <i>Blood</i> , 2006, 108, 985-985.	0.6	41
338	Disease Progression in Monoclonal B-Cell Lymphocytosis Is Independent of VH Mutation Status.. <i>Blood</i> , 2006, 108, 29-29.	0.6	0
339	Increased Expression of CD200 Antigen, a Potential Immunotherapeutic Target, Is Consistently Found in CLL Cells Irrespective of Biological Features.. <i>Blood</i> , 2006, 108, 2815-2815.	0.6	0
340	EBV Related Transformation Events in CLL.. <i>Blood</i> , 2006, 108, 4963-4963.	0.6	0
341	CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy. <i>Haematologica</i> , 2006, 91, 1577-8.	1.7	9
342	Diagnosis and management of paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2005, 106, 3699-3709.	0.6	652

#	ARTICLE	IF	CITATIONS
343	The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin. JAMA - Journal of the American Medical Association, 2005, 293, 1653.	3.8	1,324
344	Diagnostic criteria for monoclonal B-cell lymphocytosis. British Journal of Haematology, 2005, 130, 325-332.	1.2	360
345	MBL and MoBL - Response to Ziegler-Heitbrock. British Journal of Haematology, 2005, 130, 795-796.	1.2	3
346	Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. Leukemia and Lymphoma, 2005, 46, 549-552.	0.6	30
347	Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival. Journal of Clinical Oncology, 2005, 23, 2971-2979.	0.8	380
348	Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood, 2005, 106, 2559-2565.	0.6	199
349	Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood, 2005, 107, 859-861.	0.6	140
350	CD52 Expression in Waldenström's Macroglobulinemia: Implications for Alemtuzumab Therapy and Response Assessment. Clinical Lymphoma and Myeloma, 2005, 5, 278-281.	2.1	29
351	Nitric Oxide Consumption and Pulmonary Hypertension in Patients with Paroxysmal Nocturnal Hemoglobinuria.. Blood, 2005, 106, 1046-1046.	0.6	7
352	The Effect of Eculizumab Therapy on Red Cell Response Kinetics in Patients with Paroxysmal Nocturnal Hemoglobinuria.. Blood, 2005, 106, 1047-1047.	0.6	2
353	Early Results from LRF CLL4: A UK Multicenter Randomized Trial.. Blood, 2005, 106, 716-716.	0.6	27
354	Comparison of Oral and Intravenous Fludarabine in the LRF CLL4 Trial.. Blood, 2005, 106, 722-722.	0.6	3
355	Bi-Allelic Deletion of 13q14 Is Associated with Inferior Progression Free Survival Compared to Mono-Allelic 13q14 Deletion in B-Cell Chronic Lymphocytic Leukaemia.. Blood, 2005, 106, 2936-2936.	0.6	1
356	Population Pharmacokinetics of Alemtuzumab in Patients with Hematologic Malignancies.. Blood, 2005, 106, 2961-2961.	0.6	1
357	Minimal residual disease and survival in chronic lymphocytic leukemia. Clinical Advances in Hematology and Oncology, 2005, 3, 522-4.	0.3	0
358	Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria. Haematologica, 2005, 90, ECR40.	1.7	21
359	Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria. New England Journal of Medicine, 2004, 350, 552-559.	13.9	541
360	Advancing Therapy For Chronic Lymphocytic Leukemia—the Role Of Rituximab. Seminars in Oncology, 2004, 31, 22-26.	0.8	11

#	ARTICLE	IF	CITATIONS
361	Management Guidelines for Use of Alemtuzumab in B-Cell Chronic Lymphocytic Leukemia. Clinical Lymphoma and Myeloma, 2004, 4, 220-227.	2.1	91
362	Clonal lymphocytes in persons without known chronic lymphocytic leukemia (CLL): implications of recent findings in family members of CLL patients. Seminars in Hematology, 2004, 41, 192-200.	1.8	19
363	Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood, 2004, 103, 2027-2031.	0.6	64
364	Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood, 2004, 104, 948-955.	0.6	175
365	Evolution of GPI-Deficient Clones Predicts Clinical Course in Paroxysmal Nocturnal Haemoglobinuria.. Blood, 2004, 104, 172-172.	0.6	5
366	Preliminary Safety and Efficacy Report of a Randomized Trial of Alemtuzumab vs Chlorambucil as Front-Line Therapy in 297 Patients with Progressive B-Cell Chronic Lymphocytic Leukemia.. Blood, 2004, 104, 2505-2505.	0.6	7
367	Sustained Control of Hemolysis and Symptoms and Reduced Transfusion Requirements over a Period of 2 Years in Paroxysmal Nocturnal Hemoglobinuria (PNH) with Eculizumab Therapy.. Blood, 2004, 104, 2823-2823.	0.6	3
368	IgH Rearrangements and Mutational Status in Class-Switched IgG B-CLL.. Blood, 2004, 104, 2793-2793.	0.6	1
369	Advancing therapy for chronic lymphocytic leukemia—the role of rituximab. Seminars in Oncology, 2004, 31, 22-6.	0.8	18
370	Alemtuzumab therapy in B-cell lymphoproliferative disorders. Seminars in Oncology, 2003, 30, 493-501.	0.8	31
371	Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood, 2003, 102, 3587-3591.	0.6	252
372	The Glycosylphosphatidylinositol Anchor and Paroxysmal Nocturnal Haemoglobinuria/Aplasia Model. Acta Haematologica, 2002, 108, 219-230.	0.7	24
373	Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood, 2002, 100, 635-639.	0.6	305
374	Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood, 2002, 99, 3554-3561.	0.6	895
375	Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood, 2002, 99, 2245-2247.	0.6	184
376	Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood, 2002, 100, 2289-2290.	0.6	207
377	Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood, 2001, 98, 29-35.	0.6	249
378	Advances in the laboratory diagnosis of paroxysmal nocturnal hemoglobinuria. Clinical and Applied Immunology Reviews, 2001, 1, 315-330.	0.4	11

#	ARTICLE	IF	CITATIONS
379	IMPLICATIONS OF RECENT INSIGHTS INTO THE PATHOPHYSIOLOGY OF PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA. <i>British Journal of Haematology</i> , 2000, 108, 470-479.	1.2	63
380	Paroxysmal Nocturnal Hemoglobinuriaâ€™ the Selection of a Clone. <i>Reviews in Clinical and Experimental Hematology</i> , 2000, 4, 216-235.	0.1	1
381	Natural History of Paroxysmal Nocturnal Hemoglobinuria. <i>New England Journal of Medicine</i> , 1995, 333, 1253-1258.	13.9	796
382	Mutations in the PIG-A gene causing partial deficiency of GPI-linked surface proteins (PNH II) in patients with paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 1994, 87, 863-866.	1.2	63
383	Two distinct patterns of glycosylphosphatidylinositol (GPI) linked protein deficiency in the red cells of patients with paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 1992, 80, 399-405.	1.2	50